Portfolio Strategy and Opportunity Assessment to Support BD Decisions and Clinical Development

The Client

• Venture-backed pre-commercial biotech
• Novel MOA with two potentially distinct paths to market
• Direct anticancer strategy
• One based on the agent’s immunomodulatory anticancer effects

Challenge

• PC data suggest the small molecule can provide both inhibition of a common cell signaling pathway terminal kinase and may have a role in regulating T cells and their recruitment for effector function
• Identification of optimal indications based on PoC, timing to value inflection, and partnerabilty

Approach

• Systematic approach to prioritizing indications based on clinical and commercial risks and attractiveness
• Opportunity assessment on top indications to determine best positioning (including biomarker-driven strategy) to inform target product profile development
• 10-year market forecast for direct comparison between top indications

Valued Outcome

• Provided client ability to strategize portfolio by triaging indications and identified new indications that were not previously championed internally
• Provided optimal registrational settings and clinical development strategies to inform partnering discussions which led to formation of a clinical collaboration with a large biopharmaceutical entity
• Advanced clinical trials are ongoing